Medications

New drug to regenerate lost teeth

The tooth fairy is a welcome guest for any child who has lost a tooth. Not only will the fairy leave a small gift under the pillow, but the child can be assured of a new tooth in a few months. The same cannot be said of adults ...

Diseases, Conditions, Syndromes

First human challenge trial shows how COVID-19 strikes

A group of 36 volunteers have completed the first human challenge study of COVID-19, after being given the virus and then monitored to examine what happened to them after infection.

Immunology

Scientists discover a highly potent antibody against SARS-CoV-2

Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified ...

Diseases, Conditions, Syndromes

Neuropilin-1 drives SARS-CoV-2 infectivity, finds breakthrough study

In a major breakthrough an international team of scientists, led by the University of Bristol, has potentially identified what makes SARS-CoV-2 highly infectious and able to spread rapidly in human cells. The findings, published ...

Medical research

Is the first cure for advanced rabies near?

Rabies virus is incurable and almost always fatal once it has invaded the central nervous system, with the victim doomed to suffer a horrible death.

page 1 from 40

Monoclonal antibodies

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are identical because they are produced by one type of immune cell that are all clones of a single parent cell. Given almost any substance, it is possible to create monoclonal antibodies that specifically bind to that substance; they can then serve to detect or purify that substance. This has become an important tool in biochemistry, molecular biology and medicine. When used as medications, the generic drug name ends in -mab (see "Nomenclature of monoclonal antibodies").

This text uses material from Wikipedia, licensed under CC BY-SA